Spero therapeutics inc SPRO.US 總覽分析
SPRO 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
SPRO 近期報酬表現
-1.97%
Spero therapeutics inc
3.56%
同產業平均
1.47%
S&P500
與 SPRO 同產業的標的表現
- MURA Mural oncology plc價值 -趨勢 3 分波段 4 分籌碼 1 分股利 1 分查看更多
SPRO 公司資訊
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.